Display options
Cite
Hussain SS, Farhat S, Rather YH, et al. Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine-naloxone in opioid withdrawal - a hospital based study. J Clin Diagn Res. 2015;9(1):FC01-4doi: 10.7860/JCDR/2015/10625.5425.
Hussain, S. S., Farhat, S., Rather, Y. H., & Abbas, Z. (2015). Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine-naloxone in opioid withdrawal - a hospital based study. Journal of clinical and diagnostic research : JCDR, 9(1), FC01-4. https://doi.org/10.7860/JCDR/2015/10625.5425
Hussain, Syed Sajad, et al. "Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine-naloxone in opioid withdrawal - a hospital based study." Journal of clinical and diagnostic research : JCDR vol. 9,1 (2015): FC01-4. doi: https://doi.org/10.7860/JCDR/2015/10625.5425
Hussain SS, Farhat S, Rather YH, Abbas Z. Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine-naloxone in opioid withdrawal - a hospital based study. J Clin Diagn Res. 2015 Jan;9(1):FC01-4. doi: 10.7860/JCDR/2015/10625.5425. Epub 2015 Jan 01. PMID: 25738001; PMCID: PMC4347092.
Copy Download .nbib Format: NLM
Share it on

J Clin Diagn Res. 2015 Jan;9(1):FC01-4. doi: 10.7860/JCDR/2015/10625.5425. Epub 2015 Jan 01.

Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine-naloxone in opioid withdrawal - a hospital based study.

Journal of clinical and diagnostic research : JCDR

Syed Sajad Hussain, Samina Farhat, Yasir Hassan Rather, Zaffar Abbas

Affiliations

  1. Demonstrator, Department of Pharmacology, Government Medical Collage Srinagar, Jammu and Kashmir, India .
  2. Associate Professor and Head, Department of Pharmacology, GMC Srinagar, India .
  3. Lecturer, Department of Psychiatry, Institute of Mental Health and Neurosciences, GMC Srinagar, India .
  4. Professor & Head, Department of Pharmacology, Luxmi Bai Institute of Dental Sciences and Hospital , Sirhind Road Patiala Punjab, India .

PMID: 25738001 PMCID: PMC4347092 DOI: 10.7860/JCDR/2015/10625.5425

Abstract

OBJECTIVES: Prevalence of opioid addiction has alarmingly increased over the recent years. In South Asian region alone there are more than 10 million opioid abusers amounting to 2% of world population. Detoxification remains to be the first step for the successful treatment of opioid addiction. The present study was carried out to compare the relative efficacy and safety of buprenorphine -naloxone and clonidine hydrochloride in the detoxification of opioid-dependents.

MATERIALS AND METHODS: Present trial was conducted at De- addiction centre of Institute of Mental and Neurosciences (IMNS), GMC Srinagar. Fifty four (54) treatment seeking subjects, 15-50 years of age, fulfilling DSM-1V TR (American Psychiatric association`s Mental Disorders-1V text revision) criteria for opioid dependence were included and randomized into two groups. The groups received either clonidine hydrochloride (Group A) or buprenorphine- naloxone (Bup-Nax) (Group B) for the duration of 10 days. The efficacy of the two drugs in controlling the opioid withdrawal was evaluated by Clinical Opioid Withdrawal Scale (COWS) and their effect on the desire for the abused substance was measured by Visual Analogue Scale (VAS). The safety of the two drugs was measured by taking the side effect profile of the two compared drugs into consideration.

RESULTS: There was significant difference of COWS-score between the two groups which was evident from day 3 (14.85 ± 3.43 vs. 11.67 ± 2.40, p<0.005) and continued till day 6 (2.56 ± 1.40 vs. 0.30 ± 0.61, p<0.005), for Group A and group B respectively. The effect of two drugs in controlling the craving for the abused substance also showed significant difference from day 2 (66.30 ± 10.80 vs. 47.40 ± 12.90, p<0.005) till day 5 (7.78 ± 6.41 vs. 1.85 ± 6.22, p<0.005), for Group A and Group B respectively.

CONCLUSION: Administration of buprenorphine-naloxone was more efficient in reducing the signs and symptoms of opioid withdrawal and in controlling the craving for the abused substance during the first few days of detoxification.

Keywords: Buprenorphine-naloxone; Clinical opioid withdrawal scale; Clonidine; Opioid addiction; Visual analogue scale

References

  1. Addict Biol. 2000 Jan 1;5(1):65-9 - PubMed
  2. Expert Opin Pharmacother. 2004 Apr;5(4):713-25 - PubMed
  3. Drug Alcohol Depend. 2003 Apr 1;69(3):263-72 - PubMed
  4. Drug Alcohol Depend. 1994 Oct;36(2):139-45 - PubMed
  5. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD002025 - PubMed
  6. JAMA. 1980 Jan 25;243(4):343-6 - PubMed
  7. Drug Alcohol Depend. 2005 Jan 7;77(1):71-9 - PubMed
  8. Pain Physician. 2008 Mar-Apr;11(2):225-35 - PubMed
  9. Drug Alcohol Depend. 1994 Oct;36(2):115-21 - PubMed
  10. JAMA. 2005 Aug 24;294(8):903-13 - PubMed
  11. Addict Health. 2010 Winter-Spring;2(1-2):18-24 - PubMed
  12. J Addict Dis. 1994;13(3):33-45 - PubMed
  13. Addiction. 2005 Aug;100(8):1090-100 - PubMed
  14. J Subst Abuse Treat. 1993 Jul-Aug;10(4):391-4 - PubMed
  15. Arch Gen Psychiatry. 2005 Oct;62(10):1157-64 - PubMed
  16. Am J Addict. 2004;13 Suppl 1:S42-66 - PubMed

Publication Types